Sponsor
Diana Harshbarger
Representative · R-TN
Representative · R-TN
The bill increases regulatory clarity and legal recourse for manufacturers and may preserve some low‑dose or alternate‑route uses as supplements, but does so at the risk of greater consumer safety exposure and potential public costs from delayed FDA enforcement and transitional legal uncertainty.
Small-business manufacturers: gain clearer, narrower standards and seven specific exceptions that reduce enforcement uncertainty when adding certain approved drugs/biologics to foods or dietary supplements.
Manufacturers: can obtain immediate judicial review of certain FDA communications (warning letters, specified responses, website statements), shortening regulatory uncertainty and lowering business risk from enforcement actions.
Hospitals and health systems (and potentially some consumers): the FDA must consider route, dose, concentration, and degree of safety when deciding whether an approved drug/biologic use precludes regulation as a food or supplement, which could allow safe low‑dose or alternate‑route uses to remain outside drug regulation.
Consumers: could face increased safety risks if foods or dietary supplements incorporate approved drugs/biologics under the bill’s exceptions, increasing the chance of unmonitored drug effects or dangerous interactions.
Taxpayers and public health systems (including hospitals): may bear higher costs from adverse events if judicial review delays the FDA’s ability to halt unsafe products, shifting medical and financial burdens to the public sector.
Small manufacturers and regulators: narrowing the statutory definition of 'dietary supplement' could create legal uncertainty and transitional compliance costs as products are reclassified, relabeled, or otherwise adjusted to meet the new standard.
Based on analysis of 2 sections of legislative text.
Clarifies when added drugs/biologics make a food or dietary supplement unlawful, creates seven exceptions, adds factors for FDA to weigh, and allows immediate judicial review of certain FDA communications.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to encourage innovation and increase and protect consumer access with respect to dietary supplements by clarifying the regulatory framework governing drug preclusion, and for other purposes.
Introduced September 10, 2026 by Diana Harshbarger · Last progress September 10, 2026
Amends the Food, Drug, and Cosmetic Act to clarify when a food or dietary supplement that contains an added drug or biological product may be treated as an unlawful drug. It creates seven explicit exceptions to drug-preclusion, narrows the statutory dietary supplement phrasing, requires the agency to weigh specific differences (route, dose/serving, concentration/composition, and degree of safety) when deciding preclusion, and makes certain FDA communications immediately reviewable in court with the United States bearing the burden of proof.